tiprankstipranks
Trending News
More News >
RegenXBio (RGNX)
NASDAQ:RGNX
US Market
Advertisement

RegenXBio (RGNX) Stock Forecast & Price Target

Compare
953 Followers
See the Price Targets and Ratings of:

RGNX Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
RegenXBio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RGNX Stock 12 Month Forecast

Average Price Target

$25.78
▲(165.50% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for RegenXBio in the last 3 months. The average price target is $25.78 with a high forecast of $40.00 and a low forecast of $14.00. The average price target represents a 165.50% change from the last price of $9.71.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","32":"$32","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14,23,32,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.12,11.495384615384616,13.87076923076923,16.246153846153845,18.621538461538464,20.996923076923075,23.372307692307693,25.74769230769231,28.123076923076923,30.49846153846154,32.87384615384615,35.24923076923077,37.62461538461539,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.12,10.401538461538461,11.683076923076923,12.964615384615385,14.246153846153845,15.527692307692309,16.80923076923077,18.090769230769233,19.372307692307693,20.653846153846153,21.935384615384617,23.21692307692308,24.49846153846154,{"y":25.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.12,9.495384615384614,9.87076923076923,10.246153846153845,10.62153846153846,10.996923076923077,11.372307692307691,11.747692307692308,12.123076923076923,12.498461538461537,12.873846153846154,13.249230769230769,13.624615384615385,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$25.78Lowest Price Target$14.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on RGNX
Goldman Sachs
Goldman Sachs
$14
Hold
44.18%
Upside
Reiterated
09/05/25
Goldman Sachs Sticks to Its Hold Rating for RegenXBio (RGNX)Goldman Sachs analyst Paul Choi reiterated a Neutral rating and $14.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Raymond James Analyst forecast on RGNX
Raymond James
Raymond James
$29
Buy
198.66%
Upside
Reiterated
09/05/25
RegenXBio (RGNX) Receives a Buy from Raymond JamesRaymond James analyst Sean McCutcheon reiterated an Outperform rating and $29.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Stifel Nicolaus Analyst forecast on RGNX
Stifel Nicolaus
Stifel Nicolaus
$40
Buy
311.95%
Upside
Reiterated
08/19/25
Stifel Nicolaus Sticks to Their Buy Rating for RegenXBio (RGNX)Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Leerink Partners Analyst forecast on RGNX
Leerink Partners
Leerink Partners
$17
Buy
75.08%
Upside
Reiterated
08/19/25
Regenxbio FDA delay 'not a needle mover,' says LeerinkRegenxbio FDA delay 'not a needle mover,' says Leerink
H.C. Wainwright Analyst forecast on RGNX
H.C. Wainwright
H.C. Wainwright
$34
Buy
250.15%
Upside
Reiterated
08/19/25
Optimistic Buy Rating for RegenXBio Amidst Promising Gene Therapy Developments
Morgan Stanley Analyst forecast on RGNX
Morgan Stanley
Morgan Stanley
$24
Buy
147.17%
Upside
Reiterated
08/18/25
Strategic Developments and Partnerships Bolster RegenXBio's Buy Rating Amid Regulatory Delay
Barclays Analyst forecast on RGNX
Barclays
Barclays
$50$37
Buy
281.05%
Upside
Reiterated
08/08/25
Barclays Keeps Their Buy Rating on RegenXBio (RGNX)
RBC Capital Analyst forecast on RGNX
RBC Capital
RBC Capital
$21$17
Buy
75.08%
Upside
Reiterated
08/08/25
Regenxbio price target lowered to $17 from $21 at RBC CapitalRegenxbio price target lowered to $17 from $21 at RBC Capital
Bank of America Securities Analyst forecast on RGNX
Bank of America Securities
Bank of America Securities
$22$20
Buy
105.97%
Upside
Reiterated
08/08/25
RegenXBio (RGNX) Receives a Buy from Bank of America Securities
Clear Street Analyst forecast on RGNX
Clear Street
Clear Street
$50
Buy
414.93%
Upside
Initiated
03/31/25
Clear Street starts Regenxbio Inc. (RGNX) at Buy, PT $50Clear Street analyst Bill Maughan initiates coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Buy rating and a price target of $50.00.
Robert W. Baird Analyst forecast on RGNX
Robert W. Baird
Robert W. Baird
$39
Buy
301.65%
Upside
Reiterated
03/19/25
Bairds Brian Skorney Comments on Regenxbio Inc. (RGNX): We also think its favorable that REGENXBIO is able to learn from Elevidys faultsBaird analyst Brian Skorney reiterated an Outperform rating and $39.00 price target on Regenxbio Inc. (NASDAQ: RGNX)
Chardan Capital Analyst forecast on RGNX
Chardan Capital
Chardan Capital
$52
Buy
435.53%
Upside
Reiterated
11/19/24
We note that a 12-yo patient treated at DL2 did not have a matched natural history external control for NSAA, but also note that DMD patients aged 8+ yrs generally are in a rapid decline phase for NSAA, whereas the patient in the current study has a notable improvement in NSAA score. A doctor on the call noted the beneficial effects that the treatment has had on the patients' daily lives, highlighting one patient who was able to participate in a six-mile community bike ride.
Truist Financial Analyst forecast on RGNX
Truist Financial
Truist Financial
$18
Buy
85.38%
Upside
Reiterated
11/18/24
Raymond James reiterates Outperform Rating on Regenxbio Inc. (RGNX)Raymond James analyst Danielle Brill reiterated an Outperform rating and $18.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on RGNX
Goldman Sachs
Goldman Sachs
$14
Hold
44.18%
Upside
Reiterated
09/05/25
Goldman Sachs Sticks to Its Hold Rating for RegenXBio (RGNX)Goldman Sachs analyst Paul Choi reiterated a Neutral rating and $14.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Raymond James Analyst forecast on RGNX
Raymond James
Raymond James
$29
Buy
198.66%
Upside
Reiterated
09/05/25
RegenXBio (RGNX) Receives a Buy from Raymond JamesRaymond James analyst Sean McCutcheon reiterated an Outperform rating and $29.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Stifel Nicolaus Analyst forecast on RGNX
Stifel Nicolaus
Stifel Nicolaus
$40
Buy
311.95%
Upside
Reiterated
08/19/25
Stifel Nicolaus Sticks to Their Buy Rating for RegenXBio (RGNX)Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Leerink Partners Analyst forecast on RGNX
Leerink Partners
Leerink Partners
$17
Buy
75.08%
Upside
Reiterated
08/19/25
Regenxbio FDA delay 'not a needle mover,' says LeerinkRegenxbio FDA delay 'not a needle mover,' says Leerink
H.C. Wainwright Analyst forecast on RGNX
H.C. Wainwright
H.C. Wainwright
$34
Buy
250.15%
Upside
Reiterated
08/19/25
Optimistic Buy Rating for RegenXBio Amidst Promising Gene Therapy Developments
Morgan Stanley Analyst forecast on RGNX
Morgan Stanley
Morgan Stanley
$24
Buy
147.17%
Upside
Reiterated
08/18/25
Strategic Developments and Partnerships Bolster RegenXBio's Buy Rating Amid Regulatory Delay
Barclays Analyst forecast on RGNX
Barclays
Barclays
$50$37
Buy
281.05%
Upside
Reiterated
08/08/25
Barclays Keeps Their Buy Rating on RegenXBio (RGNX)
RBC Capital Analyst forecast on RGNX
RBC Capital
RBC Capital
$21$17
Buy
75.08%
Upside
Reiterated
08/08/25
Regenxbio price target lowered to $17 from $21 at RBC CapitalRegenxbio price target lowered to $17 from $21 at RBC Capital
Bank of America Securities Analyst forecast on RGNX
Bank of America Securities
Bank of America Securities
$22$20
Buy
105.97%
Upside
Reiterated
08/08/25
RegenXBio (RGNX) Receives a Buy from Bank of America Securities
Clear Street Analyst forecast on RGNX
Clear Street
Clear Street
$50
Buy
414.93%
Upside
Initiated
03/31/25
Clear Street starts Regenxbio Inc. (RGNX) at Buy, PT $50Clear Street analyst Bill Maughan initiates coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Buy rating and a price target of $50.00.
Robert W. Baird Analyst forecast on RGNX
Robert W. Baird
Robert W. Baird
$39
Buy
301.65%
Upside
Reiterated
03/19/25
Bairds Brian Skorney Comments on Regenxbio Inc. (RGNX): We also think its favorable that REGENXBIO is able to learn from Elevidys faultsBaird analyst Brian Skorney reiterated an Outperform rating and $39.00 price target on Regenxbio Inc. (NASDAQ: RGNX)
Chardan Capital Analyst forecast on RGNX
Chardan Capital
Chardan Capital
$52
Buy
435.53%
Upside
Reiterated
11/19/24
We note that a 12-yo patient treated at DL2 did not have a matched natural history external control for NSAA, but also note that DMD patients aged 8+ yrs generally are in a rapid decline phase for NSAA, whereas the patient in the current study has a notable improvement in NSAA score. A doctor on the call noted the beneficial effects that the treatment has had on the patients' daily lives, highlighting one patient who was able to participate in a six-mile community bike ride.
Truist Financial Analyst forecast on RGNX
Truist Financial
Truist Financial
$18
Buy
85.38%
Upside
Reiterated
11/18/24
Raymond James reiterates Outperform Rating on Regenxbio Inc. (RGNX)Raymond James analyst Danielle Brill reiterated an Outperform rating and $18.00 price target on Regenxbio Inc. (NASDAQ: RGNX).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RegenXBio

1 Month
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+9.49%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +9.49% per trade.
3 Months
xxx
Success Rate
6/12 ratings generated profit
50%
Average Return
-0.74%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.74% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
6/12 ratings generated profit
50%
Average Return
-6.99%
reiterated a buy rating 19 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -6.99% per trade.
2 Years
xxx
Success Rate
6/12 ratings generated profit
50%
Average Return
-3.54%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -3.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGNX Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
27
20
20
21
15
Buy
1
1
1
1
0
Hold
12
14
20
20
16
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
35
41
42
31
In the current month, RGNX has received 15 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. RGNX average Analyst price target in the past 3 months is 25.78.
Each month's total comprises the sum of three months' worth of ratings.

RGNX Financial Forecast

RGNX Earnings Forecast

Next quarter’s earnings estimate for RGNX is -$1.30 with a range of -$1.68 to -$0.89. The previous quarter’s EPS was -$1.38. RGNX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year RGNX has Outperformed its overall industry.
Next quarter’s earnings estimate for RGNX is -$1.30 with a range of -$1.68 to -$0.89. The previous quarter’s EPS was -$1.38. RGNX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year RGNX has Outperformed its overall industry.

RGNX Sales Forecast

Next quarter’s sales forecast for RGNX is $24.63M with a range of $11.66M to $45.84M. The previous quarter’s sales results were $21.36M. RGNX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 50.00% of the time in the same period. In the last calendar year RGNX has Outperformed its overall industry.
Next quarter’s sales forecast for RGNX is $24.63M with a range of $11.66M to $45.84M. The previous quarter’s sales results were $21.36M. RGNX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 50.00% of the time in the same period. In the last calendar year RGNX has Outperformed its overall industry.

RGNX Stock Forecast FAQ

What is RGNX’s average 12-month price target, according to analysts?
Based on analyst ratings, RegenXBio’s 12-month average price target is 25.78.
    What is RGNX’s upside potential, based on the analysts’ average price target?
    RegenXBio has 165.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RGNX a Buy, Sell or Hold?
          RegenXBio has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is RegenXBio’s price target?
            The average price target for RegenXBio is 25.78. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $14.00. The average price target represents 165.50% Increase from the current price of $9.71.
              What do analysts say about RegenXBio?
              RegenXBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of RGNX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis